Multinational pharmaceutical companies 2020 China performance PK!

On February 25, German pharmaceutical giant Bayer announced its 2020 fiscal year results.

China has become the world's second largest pharmaceutical market, and it can be described as a battleground for multinational pharmaceutical companies.

Eight multinational pharmaceutical companies' performance in China in 2020

(Remarks: The data comes from the financial reports of various pharmaceutical companies and is converted at the average exchange rate of each currency in 2020.

Products are king, heavyweight and innovative varieties are the pillars of performance

Specifically, blockbuster varieties and innovative products are still important pillars for multinational pharmaceutical companies to achieve revenue growth in China.

The anti-tumor product pipeline is the trump card business of AstraZeneca, which continues to hold the top spot in the performance of multinational pharmaceutical companies in China.

Pabrizol is undoubtedly the main force of Merck’s absolute revenue.

Affected by the impact of biosimilar drugs and the impact of the epidemic, Roche, which holds the three blockbuster drugs of trastuzumab, bevacizumab, and rituximab, has seen a 2% decline in its global pharmaceutical business revenue.

Policies superimposed on epidemic giants' revenue growth is generally weak

Unlike the situation where several multinational pharmaceutical companies achieved revenue growth of more than 30% in 2019, the overall revenue growth of foreign giants in 2020 is generally weak.

In addition to pembrolizumab, the cervical cancer vaccine Gardasil 9 and the reversing neuromuscular block drug Bridion (sugammadex sodium) are two other blockbuster products that Merck relies on, but its market growth rate in 2020 Significant slowdown, Merck admitted that the main reason is that the new crown epidemic has affected HPV vaccination and the number of surgical operations in hospitals.

However, China is the first pharmaceutical market to recover economic vitality from the impact of the new crown epidemic.

Although both innovative drugs and vaccine businesses have brought good sales growth momentum to Sanofi, the performance of mature brand drugs has affected the overall performance, especially clopidogrel (Plavix) and Erbe, which have been popular in the Chinese market in the past.

AstraZeneca, which has won the performance champion in China, also cannot avoid the impact of large-volume purchases.

Focus on innovative drugs and local innovation forces are gradually becoming a trend

Some analysts pointed out that since the implementation of the medical insurance negotiation catalogue, the stable price system of foreign pharmaceutical companies has been gradually broken.

Eli Lilly, which disclosed China's performance for the first time, attracted the attention of the industry with the highest year-on-year growth rate of 19%.

Coincidentally, Novartis, whose performance growth rate in China is second only to Eli Lilly, is also favoring local innovative pharmaceutical companies.

The industry generally believes that under the influence of policies such as mass procurement and national medical insurance negotiations, the structure of China's pharmaceutical market has changed.